Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
05:47am, Monday, 12'th Jan 2026
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
CoreCap Advisors LLC Purchases Shares of 4,743 Incyte Corporation $INCY
04:06am, Monday, 12'th Jan 2026
CoreCap Advisors LLC purchased a new stake in shares of Incyte Corporation (NASDAQ: INCY) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 4,74
Mohamed Khairie Issa Sells 10,856 Shares of Incyte (NASDAQ:INCY) Stock
05:04am, Saturday, 10'th Jan 2026
Incyte Corporation (NASDAQ: INCY - Get Free Report) EVP Mohamed Khairie Issa sold 10,856 shares of the company's stock in a transaction dated Wednesday, January 7th. The shares were sold at an average
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Wednesday, 07'th Jan 2026
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins
02:18pm, Tuesday, 06'th Jan 2026
Incyte Corporation remains a Buy, driven by robust Hem/Oncology portfolio growth and key Monjuvi/Minjuvi expansion catalysts. INCY's Hem/Onc portfolio revenues surged 107% YoY in Q3 2025, fueled by Mo
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
11:20am, Tuesday, 06'th Jan 2026
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer
11:59am, Monday, 05'th Jan 2026
Incyte Corporation (NASDAQ: INCY) on Monday shared topline results from the pivotal Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) combo as a first-line treatment for adults with newly diagn
Incyte's blood cancer therapy meets main goal in late-stage trial
07:40am, Monday, 05'th Jan 2026
Incyte said on Monday its experimental combo therapy met the main goal in a late-stage trial testing patients with a type of blood cancer.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for DLBCL.
CWA Asset Management Group LLC Acquires New Holdings in Incyte Corporation $INCY
04:26am, Monday, 05'th Jan 2026
CWA Asset Management Group LLC bought a new position in Incyte Corporation (NASDAQ: INCY) during the undefined quarter, according to its most recent filing with the SEC. The institutional investor bou
Generali Asset Management SPA SGR Reduces Holdings in Incyte Corporation $INCY
05:36am, Sunday, 04'th Jan 2026
Generali Asset Management SPA SGR reduced its stake in Incyte Corporation (NASDAQ: INCY) by 20.3% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commiss
Perigon Wealth Management LLC Purchases Shares of 5,365 Incyte Corporation $INCY
05:18am, Saturday, 03'rd Jan 2026
Perigon Wealth Management LLC purchased a new stake in shares of Incyte Corporation (NASDAQ: INCY) during the undefined quarter, according to its most recent filing with the Securities and Exchange Co
Continuum Advisory LLC Buys 5,185 Shares of Incyte Corporation $INCY
05:01am, Tuesday, 30'th Dec 2025
Continuum Advisory LLC increased its stake in Incyte Corporation (NASDAQ: INCY) by 7.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Co
22,200 Shares in Incyte Corporation $INCY Purchased by Burney Co.
04:50am, Sunday, 28'th Dec 2025
Burney Co. bought a new stake in Incyte Corporation (NASDAQ: INCY) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institution
Incyte (NASDAQ:INCY) Insider Thomas Tray Sells 600 Shares of Stock
06:05am, Tuesday, 23'rd Dec 2025
Incyte Corporation (NASDAQ: INCY - Get Free Report) insider Thomas Tray sold 600 shares of Incyte stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average pric
